The initial contributors in a Section II/III trial for AstraZeneca’s new COVID-19 variant vaccine AZD2816 are already vaccinated to evaluate its basic safety and immunogenicity in the two Beforehand vaccinated and unvaccinated adults. The submission into the Hungarian Regulatory Authority OGYEI for approval to start a scientific section 2b trial https://carrieb208srq3.bimmwiki.com/user